ARS Pharmaceuticals, Inc. (SPRY) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
the bull case· 3
20
disclosed supplier and customer ties in sec filings
sec filingsedgar4
of the funds on file reporting a position in spry
n-portas of Jun 30 '26+4.36%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 2
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized4 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 10 '26 report. Not a forecast, not advice.
tall tick = annual report · 1 on record
205 managers report a position worth $728.8M between them, and 17 of them hold 80% of it.
ARS Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 4.19 at 5:45 pm ET, low 4.11 at 4:00 pm ET.
SPRY (ARS Pharmaceuticals, Inc.) has 12 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Of the 6 companies ARS Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.